GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (MEX:ABT) » Definitions » Net Change in Cash

Abbott Laboratories (MEX:ABT) Net Change in Cash : MXN17,139 Mil (TTM As of Sep. 2024)


View and export this data going back to 1937. Start your Free Trial

What is Abbott Laboratories Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Abbott Laboratories's Net Change in Cash for the three months ended in Sep. 2024 was MXN11,243 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was MXN17,139 Mil.

Abbott Laboratories Net Change in Cash Historical Data

The historical data trend for Abbott Laboratories's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Net Change in Cash Chart

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 301.76 59,238.38 60,741.95 1,618.17 -50,685.10

Abbott Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19,613.68 3,174.18 -10,156.91 12,879.03 11,243.16

Abbott Laboratories Net Change in Cash Calculation

Abbott Laboratories's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=123250.015+-53180.319+-120364.392+-390.408
=-50,685

Abbott Laboratories's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=53262.262+-11696.038+-31031.913+708.851
=11,243

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN17,139 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbott Laboratories Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (MEX:ABT) » Definitions » Net Change in Cash
Comparable Companies
SYK BSX MDT EW DXCM ZBH STE PODD GMED PEN XTER:SHL SZSE:300760 XAMS:PHIA XSWX:SOON SHSE:688271 ASX:COH LSE:SN. BIO MASI BRKR
Traded in Other Exchanges
ABT:USA ABLd:UK ABL:Germany ABL:Germany ABL:Germany ABL:Germany ABTT34:Brazil ABL:Bulgaria ABT:Austria ABT:Argentina
Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Website
https://www.abbottinvestor.com
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.